Finance entity
JNJ-2113 is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 21-day span, the pace is roughly 0.7 stories per week. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Jun 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
JNJ-2113 is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 21-day span, the pace is roughly 0.7 stories per week. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. At 5.5, the average consequence score sits below the same-window beat average of 6.3. Protagonist Therapeutics appears in 2 tracked Finance stories published from February 25, 2026 through March 17, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1697 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protagonist Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings Release
Official financial results and conference calls scheduled for both companies.
Pre-Earnings Market Activity
Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
Takeda Deal Restructuring
Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Protagonist Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
